Opioid Quota Reform Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Mar 12, 2018)
Opioid Quota Reform Act
This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone.
Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.
What just happenedJun 19, 2018
Placed on Senate Legislative Calendar under General Orders. Calendar No. 473.
Who’s behind it
- Reported to SenateJun 19, 2018
- Introduced in SenateMar 12, 2018
- Jun 19, 2018Calendars
Placed on Senate Legislative Calendar under General Orders. Calendar No. 473.
- Jun 19, 2018Committee
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Judiciary Committee - Jun 19, 2018Committee14000
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Judiciary Committee - May 24, 2018Committee
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Judiciary Committee - Mar 12, 2018IntroReferral
Read twice and referred to the Committee on the Judiciary. (text of measure as introduced: CR S1632)
Judiciary Committee - Mar 12, 2018IntroReferral10000
Introduced in Senate